Merrimack Pharmaceuticals Announces the Addition of Cancer Research Pioneer John Mendelsohn, M.D. to Its Board of Directors
Dr. Mendelsohn, an internationally recognized leader in cancer research, served as president of MD Anderson from 1996 to 2011 and remains on the faculty as co-director of the new
"John's contributions to the advancement of cancer therapy and his vision for the future of predictive medicine in cancer care continue to break new ground," said
Mendelsohn earned his bachelor's degree in sciences magna cum laude from
"I am delighted to join the board and the scientists at Merrimack. The company has an approach to developing the next generation of cancer therapies, which takes advantage of new knowledge in systems biology and interlocking signaling pathways to identify optimal targets. This strategy also enables early identification of biomarkers that may predict which cancer patients are likely to benefit from the new therapies," said Mendelsohn. "I entered the field of targeted cancer therapy in 1980 and I am excited about the acceleration of progress that is occurring now as we learn how to use the new knowledge and the sophisticated tools that have been developed for biomedical research."
Merrimack also announced today the resignation of
"Walter has made a phenomenal contribution to Merrimack during his tenure as a director, and we look forward to our continued collaboration as he now focuses on our clinical development pipeline," said
Dr. Mendelsohn joins Board members
About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.
Forward-looking statements
Any statements in this press release about Merrimack's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
CONTACT:Source:Kathleen Petrozzelli Gallagher , Corporate Communications Merrimack, 617-441-1043, kgallagher@merrimackpharma.comBetsy Stevenson ,RaymondStevenson Healthcare Communications 860-984-1424, betsy@raymondstevenson.com
News Provided by Acquire Media